The pneumococcal alpha-glycerophosphate oxidase enhances nasopharyngeal colonization through binding to host glycoconjugates
Files
(Published Version)
Date
2017
Authors
Mahdi, L.
Higgins, M.
Day, C.
Tiralongo, J.
Hartley-Tassell, L.
Jennings, M.
Gordon, D.
Paton, A.
Paton, J.
Ogunniyi, A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
EBioMedicine, 2017; 18:236-243
Statement of Responsibility
Layla K. Mahdi, Melanie A. Higgins, Christopher J. Day, Joe Tiralongo, Lauren E. Hartley-Tassell, Michael P. Jennings, David L. Gordon, Adrienne W. Paton, James C. Paton, Abiodun D. Ogunniyi
Conference Name
Abstract
Streptococcus pneumoniae (the pneumococcus) is a major human pathogen, causing a broad spectrum of diseases including otitis media, pneumonia, bacteraemia and meningitis. Here we examined the role of a potential pneumococcal meningitis vaccine antigen, alpha-glycerophosphate oxidase (SpGlpO), in nasopharyngeal colonization. We found that serotype 4 and serotype 6A strains deficient in SpGlpO have significantly reduced capacity to colonize the nasopharynx of mice, and were significantly defective in adherence to human nasopharyngeal carcinoma cells in vitro. We also demonstrate that intranasal immunization with recombinant SpGlpO significantly protects mice against subsequent nasal colonization by wild type serotype 4 and serotype 6A strains. Furthermore, we show that SpGlpO binds strongly to lacto/neolacto/ganglio host glycan structures containing the GlcNAcβ1-3Galβ disaccharide, suggesting that SpGlpO enhances colonization of the nasopharynx through its binding to host glycoconjugates. We propose that SpGlpO is a promising vaccine candidate against pneumococcal carriage, and warrants inclusion in a multi-component protein vaccine formulation that can provide robust, serotype-independent protection against all forms of pneumococcal disease.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).